news 
Title: Inside Takeda’s Plasma-Derived Therapy Ecosystem
In a conversation with Forbes, Takeda’s head of plasma-derived therapies, Platford, reflected on the need to diversify sources of plasma supply, emphasizing the industry’s over-reliance on the U.S. As he acknowledged, “I think we should all be uncomfortable with that.” He also highlighted the recent surge in interest from governments regarding supply-chain sovereignty, which could lead to more countries taking responsibility for their own plasma supply.
One of the key strategies Takeda is employing is engaging patients and patient advocacy groups early on in the research and development process. This approach ensures that treatments meet real-world patient needs and are designed with efficacy and safety endpoints that align with those needs. Additionally, the company is actively promoting trust, reputation, and business (PTRB) as guiding principles for all decision-making processes.
Furthermore, Platford emphasized the importance of educating plasma donors about the impact their donations have on patients’ lives. By connecting donors to patients through various channels such as posters, videos, and learning sessions, Takeda aims to instill a sense of purpose among its plasma donors.
Looking ahead, the biggest challenges in the plasma business will likely stem from unmet medical needs and ensuring equitable access to these treatments globally. Platford believes that increasing efficiency and productivity through technology could help address affordability and accessibility issues, ultimately driving down costs.
Over the next decade, Takeda is poised to face significant growth opportunities as demand for plasma-derived therapies continues to rise due to improved diagnosis rates, better standards of care, and new therapeutic applications. However, this growth will require addressing critical supply-chain concerns and ensuring that more countries take on a greater role in providing their own plasma supplies.
In conclusion, Takeda’s approach to the plasma industry involves not only prioritizing patient needs but also recognizing the crucial importance of diversifying sources and increasing transparency throughout the process.
Source: http://www.forbes.com
